Análisis radiómico PET intra y peritumoral para predecir la respuesta patológica en pacientes con cáncer de mama que reciben quimioterapia neoadyuvante

Abstract

Objective

The aim of our study was to evaluate the contribution of ¹⁸Fluorine-fluorodeoxyglucose positron emission tomography (18F-FDG PET) radiomic data obtained from both the tumoral and peritumoral area in predicting pathological complete response (pCR) in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy (NAC).

Methods

Female patients with a diagnosis of invasive ductal carcinoma who received NAC were evaluated retrospectively. The volume of interest (VOI) of the primary tumor (VOI-_T) was manually segmented, then a voxel-thick VOI was added around VOI-_T to define the peritumoral area (VOI-_PT). Morphological, intensity-based, histogram and texture parameters were obtained from VOIs. The patients were divided into two groups as pCR and non-complete pathological response (npCR). A «radiomic model» was created with only radiomic features, and a «patho-radiomic model» was created using radiomic features and immunohistochemical data.

Results

Of the 66 patients included in the study, 21 were in the pCR group. The only statistically significant feature from the primary tumor among patients with pCR and npCR was Morphological_Compacity-_T (AUC: 0.666). Between response groups, a significant difference was detected in 2 morphological, 1 intensity, 4 texture features from VOI-_PT; no correlation was found between Morphological_Compacity-_PT and NGLDM_contrast-_PT. The obtained radiomic model's sensitivity and accuracy values were calculated as 61.9% and 75.8%, respectively (AUC: 0.786). When HER2 status was added, sensitivity and accuracy values of the patho-radiomic model increased to 85.7% and 81.8%, respectively (AUC: 0.903).

Conclusions

Evaluation of PET peritumoral radiomic features together with the primary tumor, rather than just the primary tumor, provides a better prediction of the pCR to NAC in patients with breast cancer.